Drug Profile
Aclimostat - Larimar Therapeutics
Alternative Names: Aclimostat; ZGN-1061Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Zafgen
- Developer Larimar Therapeutics
- Class Alkenes; Antihyperglycaemics; Azetidines; Carbamates; Hepatoprotectants; Morpholines; Obesity therapies; Small molecules; Spiro compounds
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- No development reported Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 29 May 2020 Chondrial Therapeutics has merged with Zafgen to form Larimar Therapeutics
- 28 Oct 2019 No recent reports of development identified for phase-I development in Obesity in Netherlands (SC, Injection)